Dermatology Medical Library

HUMAN GRANULOCYTIC ANAPLASMOSIS

Properties2
tags็šฎ่†š็ง‘, human_granulocytic_anaplasmosis, anaplasma_phagocytophilum, ixodes, tick_borne_disease, sweet_syndrome, doxycycline
aliasesไบบ้กž้ก†็ฒ’็ƒๅž‹็„กๅฝข้ซ”็—…, Human Granulocytic Anaplasmosis, HGA, HGE, Anaplasma phagocytophilum

1 min read

๐Ÿ—‚ ็ธฝ็›ฎ้Œ„ ๏ฝœ ๐Ÿ“– ่‹ฑๆ–‡ๅŽŸๆ–‡๏ผˆๆœฌ็ฏ‡๏ผ‰ ๏ฝœ ๐Ÿ“ ๅฎŒๆ•ด็ฟป่ญฏ ๏ฝœ โญ ็ฒพ่ฏ็ญ†่จ˜

HUMAN GRANULOCYTIC ANAPLASMOSIS

Anaplasma phagocytophilum, previously referred to as the โ€œhuman granulocytic ehrlichiosis (HGE) agentโ€, is an obligately intracellular bacterium (closely related to Ehrlichia spp.) that causes human granulocytic anaplasmosis (HGA; formerly known as HGE). HGA occurs in the same geographic distribution as Lyme disease (and babesiosis) owing to their transmission by the same Ixodes spp. tick vectors (see Table 76.1 & Fig. 76.12C). The clinical features of HGA are similar to those of HME, but HGA has a lower case fatality rate (0.5%โ€“1%), often presents with peripheral neuropathy (but rarely meningoencephalitis), and seldom (โ‰ค5% of patients) has dermatologic manifestations other than petechiae or purpura related to thrombocytopenia. Interestingly, Sweet syndrome has been described in association with HGA. As for HME, the first-line treatment is doxycycline.

Table 76.1 Epidemiology of rickettsial and related infections.